<SEC-DOCUMENT>0001571049-17-008778.txt : 20171229
<SEC-HEADER>0001571049-17-008778.hdr.sgml : 20171229
<ACCEPTANCE-DATETIME>20171229161900
ACCESSION NUMBER:		0001571049-17-008778
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		5
FILED AS OF DATE:		20171229
DATE AS OF CHANGE:		20171229

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVAVAX INC
		CENTRAL INDEX KEY:			0001000694
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				222816046
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-222365
		FILM NUMBER:		171282155

	BUSINESS ADDRESS:	
		STREET 1:		20 FIRSTFIELD ROAD
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20878
		BUSINESS PHONE:		240-268-2000

	MAIL ADDRESS:	
		STREET 1:		20 FIRSTFIELD ROAD
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20878
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>tv482183-s3.htm
<DESCRIPTION>S-3
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
  <head>
    <title>tv482183-s3 - none - 1.1435986s</title>
  </head>
  <body style="width:595.31pt;">
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:19pt;margin-bottom:21.71pt;margin-left:27pt;width:541pt;">
        <div style="margin-top:12pt; text-align:center; width:541pt; line-height:9pt;font-weight:bold;">As filed with the Securities and Exchange Commission on December&#160;29, 2017 </div>
        <div style="margin-top:-2pt; text-align:right; width:541pt; line-height:9pt;font-weight:bold;">Registration No. 333-&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8203;</div>
        <div style="margin-top:1.7pt; width:541pt;">
          <div style="margin-left: 0pt; width: 541pt; margin-top: 0pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3pt; width:541pt;">
          <div style="margin-left: 0pt; width: 541pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:5pt; text-align:center; width:541pt; line-height:8.5pt;font-weight:bold;">UNITED STATES <br >SECURITIES AND EXCHANGE COMMISSION <br >WASHINGTON, D.C. 20549 </div>
        <div style="margin-top:5.2pt; text-align:center; width:541pt;">
          <div style="margin-left: 40.018%; margin-right: 40.018%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:6pt; text-align:center; width:541pt; line-height:8.5pt;font-weight:bold;">FORM S-3 <br >REGISTRATION STATEMENT <br >UNDER THE SECURITIES ACT OF 1933 </div>
        <div style="margin-top:5.2pt; text-align:center; width:541pt;">
          <div style="margin-left: 40.018%; margin-right: 40.018%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:6pt; text-align:center; width:541pt; line-height:16pt;font-weight:bold;font-size:16pt;">NOVAVAX, INC.</div>
        <div style="margin-top:-2.8pt; text-align:center; width:541pt; line-height:10pt;">(Exact name of registrant as specified in its charter)</div>
        <table style="width:541pt;height:49.5pt;margin-top:2pt;border-collapse: collapse;">
          <tr style="line-height:8.00000000000001pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:264.5pt;">
              <div style="text-align:center;">Delaware </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:264.5pt;">
              <div style="text-align:center;">22-2816046 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.25pt 0pt 0.5pt 0pt; width:264.5pt;">
              <div style="text-align:center;">(State or other jurisdiction of incorporation or organization) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.25pt 0pt 0.5pt 0pt; width:264.5pt;">
              <div style="text-align:center;">(I.R.S. Employer Identification Number) </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.25pt 0pt 0.5pt 0pt; width:0pt;" colspan="4">
              <div style="text-align:center;">20 Firstfield Road <br >Gaithersburg, Maryland 20878 <br >(240) 268-2000</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.25pt 0pt 0.5pt 0pt; width:0pt;" colspan="4">
              <div style="text-align:center;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:3.69pt; text-align:center; width:541pt;">
          <div style="margin-left: 40.018%; margin-right: 40.018%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:5pt; text-align:center; width:541pt; line-height:8pt;font-weight:bold;">John A. Herrmann III <br >Senior Vice President, General Counsel and Corporate Secretary <br >Novavax, Inc. <br >20 Firstfield Road <br >Gaithersburg, Maryland 20878 <br >(240) 268-2000 <br ><font style="font-weight:normal;">(Name and address, including zip code, and telephone number, including area code, of agent for service of process for registrant)</font></div>
        <div style="margin-top:5.7pt; text-align:center; width:541pt;">
          <div style="margin-left: 40.018%; margin-right: 40.018%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:5pt; text-align:center; width:541pt; line-height:9pt;font-weight:bold;">With copies to: </div>
        <div style="margin-top:3pt; text-align:center; width:541pt; line-height:8pt;font-weight:bold;">Paul M. Kinsella <br >Ropes &amp; Gray LLP <br >800 Boylston Street <br >Boston, Massachusetts 02199 <br >(617) 951-7000</div>
        <div style="margin-top:4.7pt; text-align:center; width:541pt;">
          <div style="margin-left: 40.018%; margin-right: 40.018%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-left:20pt; margin-top:5.2pt; width:521pt; line-height:8pt;font-weight:bold;">Approximate date of commencement of proposed sale to the public:<font style="font-weight:normal;"> From time to time after the effective date of this Registration Statement. </font></div>
        <div style="text-indent:20pt; margin-top:1pt; width:541pt; line-height:8pt;">If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. &#9744;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:541pt; line-height:8pt;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&#160;415 under the Securities Act of 1933, other than securities offered only in connection with the dividend or interest reinvestment plans, check the following box. &#9744;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:541pt; line-height:8pt;">If this Form is filed to register additional securities for an offering pursuant to Rule&#160;462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:541pt; line-height:8pt;">If this Form is a post-effective amendment filed pursuant to Rule&#160;462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:541pt; line-height:8pt;">If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule&#160;462(e) under the Securities Act, check the following box. &#9744;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:541pt; line-height:8pt;">If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule&#160;413(b) under the Securities Act, check the following box. &#9744;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:541pt; line-height:8pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of&#8201; &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act. (Check one): </div>
        <table style="width:501pt;height:25pt;margin-left:20pt;margin-top:3pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:112.5pt;">Large accelerated filer</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:204pt;">&#9746;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:106.5pt;">Accelerated filer</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0.5pt 0.5pt 0pt; width:42pt;text-align:right;">
              <div style="text-align:right;">&#9744;&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.25pt 0pt 0.5pt 0pt; width:112.5pt;">Non-accelerated filer</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.25pt 0pt 0.5pt 0pt; width:204pt;">&#9744; (Do not check if a smaller reporting company) </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.25pt 0pt 0.5pt 0pt; width:106.5pt;">Smaller reporting company</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.25pt 0.5pt 0.5pt 0pt; width:42pt;text-align:right;">
              <div style="text-align:right;">&#9744;&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.25pt 0pt 0.5pt 0pt; width:112.5pt;">Emerging growth company</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.25pt 0pt 0.5pt 0pt; width:204pt;">&#9744;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:106.5pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:6.4pt; width:541pt; line-height:8pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. &#9744;</div>
        <table style="width:541pt;height:73.0000000000001pt;margin-top:5pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:3px double #000000;padding:0pt 0pt 1pt 0pt; width:0pt;" colspan="25">
              <div style="white-space:nowrap; text-align:center;">CALCULATION OF REGISTRATION FEE </div>
            </td>
            <td style="padding:0pt;border-bottom:3px double #000000; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0.75pt 0pt 1pt 0pt; width:171.67pt;text-align:left;">
              <div style="white-space:nowrap;">Title of each class of securities to be registered </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0.75pt 0pt 1pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Amount to be registered<font style=" position:relative; bottom:3.25pt;font-size:6pt;">(1)(2)</font></div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0.75pt 0pt 1pt 0pt;" colspan="4">
              <div style="text-align:center;">Proposed maximum <br >offering price per unit<font style=" position:relative; bottom:3.25pt;font-size:6pt;">(2)</font></div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0.75pt 0pt 1pt 0pt;" colspan="4">
              <div style="text-align:center;">Proposed maximum <br >aggregate offering price<font style=" position:relative; bottom:3.25pt;font-size:6pt;">(2)(3)</font></div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0.75pt 0pt 1pt 0pt;" colspan="4">
              <div style="text-align:center;">Amount of <br >registration fee<font style=" position:relative; bottom:3.25pt;font-size:6pt;">(4)</font></div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:1.25pt 0pt 0.5pt 0pt; width:171.67pt;">
              <div style="white-space:nowrap;">Common Stock, $0.01 par value<font style=" position:relative; bottom:3.25pt;font-size:6pt;">(5)</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:1.5pt 0pt 0.5pt 0pt; width:171.67pt;">
              <div style="white-space:nowrap;">Preferred Stock, $0.01 par value<font style=" position:relative; bottom:3.25pt;font-size:6pt;">(5)</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:1.5pt 0pt 0.5pt 0pt; width:171.67pt;">
              <div style="white-space:nowrap;">Warrants </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:1.5pt 0pt 0.5pt 0pt; width:171.67pt;text-align:left;">
              <div style="white-space:nowrap;">Units </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:24.315pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:30pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:24.315pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:25.365pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:25.365pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:24.275pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:30pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:24.275pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.28pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.28pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:3px double #000000;padding:1.25pt 0pt 1pt 0pt; width:171.67pt;text-align:left;">
              <div style="white-space:nowrap;">Total </div>
            </td>
            <td style="padding:0pt;border-bottom:3px double #000000; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:3px double #000000; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:24.315pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:1.25pt 0pt 1pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:1.25pt 0pt 1pt 0pt;border-bottom:3px double #000000; min-width:30pt; text-align:right; white-space:nowrap;">200,000,000</td>
            <td style="padding:0pt;padding-left:24.315pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:3px double #000000; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:3px double #000000; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:25.365pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:1.25pt 0pt 1pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.25pt 0pt 1pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">&nbsp;&nbsp;&nbsp;&#8199;&#8199;&#8199;&#8212;</td>
            <td style="padding:0pt;padding-left:25.365pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:3px double #000000; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:3px double #000000; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:24.275pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:1.25pt 0pt 1pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:1.25pt 0pt 1pt 0pt;border-bottom:3px double #000000; min-width:30pt; text-align:right; white-space:nowrap;">200,000,000</td>
            <td style="padding:0pt;padding-left:24.275pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:3px double #000000; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:3px double #000000; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.28pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:1.25pt 0pt 1pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:1.25pt 0pt 1pt 0pt;border-bottom:3px double #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">24,900</td>
            <td style="padding:0pt;padding-left:15.28pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:3px double #000000; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style=" float:left; line-height:8pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" float:left; margin-top:4pt; margin-bottom:0pt; line-height:8pt; text-align:left; width:520.5pt;">There are being registered hereunder such indeterminate number of shares of common stock and preferred stock of Novavax, Inc., such indeterminate number of warrants to purchase common stock or preferred stock of Novavax, and such indeterminate number of&#160;units consisting of any two or more of the other securities listed in the table above and sold together as shall have an aggregate initial offering price not to exceed $200,000,000 or the equivalent thereof in one or more other currencies. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:8pt; margin-top:0pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
        <div style=" float:left; margin-top:0pt; margin-bottom:0pt; line-height:8pt; text-align:left; width:520.5pt;">Not specified as to each class of securities to be registered hereunder pursuant to General Instruction II.D. of Form S-3. Any securities registered hereunder may be sold separately or as&#160;units with other securities registered hereunder. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:8pt; margin-top:0pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(3)<br ></div>
        <div style=" float:left; margin-top:0pt; margin-bottom:0pt; line-height:8pt; text-align:left; width:520.5pt;">Estimated solely for the purpose of calculating the amount of the registration fee required pursuant to Rule&#160;457(o) under the Securities Act. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:8pt; margin-top:0pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(4)<br ></div>
        <div style=" float:left; margin-top:0pt; margin-bottom:0pt; line-height:8pt; text-align:left; width:520.5pt;">Calculated pursuant to Rule&#160;457(o) under the Securities Act. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:8pt; margin-top:0pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(5)<br ></div>
        <div style=" float:left; margin-top:0pt; margin-bottom:0pt; line-height:8pt; text-align:left; width:520.5pt;">Also includes an indeterminate number of shares of common stock that may be issued upon conversion or exercise, as applicable, of preferred stock or warrants registered hereunder and an indeterminate number of shares of preferred stock that may be issued upon exercise of warrants registered hereunder.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:4pt; width:541pt; line-height:8pt;">THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(a) OF THE SECURITIES ACT OF 1933, AS AMENDED, OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME EFFECTIVE ON SUCH DATE AS THE SECURITIES AND EXCHANGE COMMISSION, ACTING PURSUANT TO SAID SECTION 8(a), MAY DETERMINE.</div>
        <div style="margin-top:0.9pt; width:541pt;">
          <div style="margin-left: 0pt; width: 541pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3pt; width:541pt;">
          <div style="margin-left: 0pt; width: 541pt; margin-top: 0pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:28pt;margin-bottom:21.71pt;margin-left:88pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:9.5pt;color:#FC0014;font-family:Helvetica, Arial, sans-serif;font-size:8pt;">The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;color:#FC0014;">Subject to Completion, Dated December 29, 2017</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;">PROSPECTUS </div>
        <div style="position:relative;z-index:-1;margin-top:6pt; text-align:center; width:456pt;">
          <img src="lg_novavax.jpg" alt="[MISSING IMAGE: lg_novavax.jpg]" height="47" width="300" >
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:17pt;font-size:16pt;">Novavax, Inc. </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:13pt;font-size:12pt;">$200,000,000 </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:13pt;font-size:12pt;">Common Stock <br >Preferred Stock <br >Warrants <br >Units </div>
        <div style="text-indent:20pt; margin-top:12pt; width:456pt; line-height:12pt;font-weight:normal;">We may issue and sell from time to time our common stock, preferred stock, warrants and/or&#160;units consisting of two or more of any such securities on terms to be determined at the time of sale. The preferred stock may be convertible into shares of our common stock, and the warrants may be exercisable for shares of our common stock or shares of our preferred stock. We may offer these securities separately or together in one or more offerings with a maximum aggregate offering price of&#8201; $200,000,000. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;font-weight:normal;">We will provide a prospectus supplement each time we issue securities, specifying the terms of the securities being sold as well as the terms of that offering. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;font-weight:normal;">You should read this prospectus and any prospectus supplement, including any information incorporated herein and therein by reference, carefully before you invest. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;font-weight:normal;">The securities may be sold directly by us, through dealers, agents or underwriters designated from time to time, or through any combination of these methods. If dealers, agents or underwriters are involved in a particular sale, we will disclose their names and the nature of our arrangements with them in the applicable prospectus supplement. The net proceeds we expect to receive from any sale also will be included in the applicable prospectus supplement. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;font-weight:normal;">Our common stock is traded on the Nasdaq Global Select Market, or Nasdaq, under the symbol &#8220;NVAX.&#8221; On December&#160;21, 2017, the closing price of our common stock as reported on Nasdaq was $1.15 per share. None of the other securities offered under this prospectus are publicly traded. </div>
        <div style="margin-top:18.48pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:20pt; margin-top:13.98pt; width:456pt; line-height:14pt;font-style:italic;font-size:12pt;">Investing in these securities involves a high degree of risk. See &#8220;RISK FACTORS&#8221; on&#160;page <a href="#t4RF">3</a>. </div>
        <div style="margin-top:12.823pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:20pt; margin-top:13.98pt; width:456pt; line-height:12pt;">This prospectus may not be used to offer or sell securities unless accompanied by a prospectus supplement for the securities being sold. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;">The date of this Prospectus is &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;. </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC">&#8203;&#8203;</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">TABLE OF CONTENTS </div>
        <table style="width:456pt;height:218pt;margin-top:7pt;border-collapse: collapse;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1.5pt 0pt; width:414pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#t1ATP">ABOUT THIS PROSPECTUS </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;"><a href="#t1ATP">1</a></td>
            <td style="padding:0pt;padding-left:10pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#t2PS">PROSPECTUS SUMMARY </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;"><a href="#t2PS">2</a></td>
            <td style="padding:0pt;padding-left:10pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#t3NVX">NOVAVAX </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;"><a href="#t3NVX">2</a></td>
            <td style="padding:0pt;padding-left:10pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#t4RF">RISK FACTORS </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;"><a href="#t4RF">3</a></td>
            <td style="padding:0pt;padding-left:10pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#t5UOP">USE OF PROCEEDS </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;"><a href="#t5UOP">3</a></td>
            <td style="padding:0pt;padding-left:10pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#t6POD">PLAN OF DISTRIBUTION </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;"><a href="#t6POD">3</a></td>
            <td style="padding:0pt;padding-left:10pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#t7DOOCS">DESCRIPTION OF OUR CAPITAL STOCK </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;"><a href="#t7DOOCS">5</a></td>
            <td style="padding:0pt;padding-left:10pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#t8DOW">DESCRIPTION OF WARRANTS </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;"><a href="#t8DOW">8</a></td>
            <td style="padding:0pt;padding-left:10pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#t9DOOU">DESCRIPTION OF OUR UNITS </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;"><a href="#t9DOOU">9</a></td>
            <td style="padding:0pt;padding-left:10pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#t10DP">DIVIDEND POLICY </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;"><a href="#t10DP">9</a></td>
            <td style="padding:0pt;padding-left:10pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#t11LM">LEGAL MATTERS </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;"><a href="#t11LM">9</a></td>
            <td style="padding:0pt;padding-left:10pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#t12EXP">EXPERTS </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;"><a href="#t12EXP">9</a></td>
            <td style="padding:0pt;padding-left:10pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#t13WYCFMI">WHERE YOU CAN FIND MORE INFORMATION </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;"><a href="#t13WYCFMI">9</a></td>
            <td style="padding:0pt;padding-left:10pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#t14IOCIBR">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;"><a href="#t14IOCIBR">10</a></td>
            <td style="padding:0pt;padding-left:10pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">i</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="t1ATP">&#8203;</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">ABOUT THIS PROSPECTUS </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">This prospectus is part of a &#8220;shelf&#8217; registration statement that we filed with the Securities and Exchange Commission (the &#8220;SEC&#8221; or &#8220;Commission&#8221;) on December&#160;29, 2017. By using a shelf registration statement, we may, from time to time, issue and sell common stock, preferred stock, warrants and/or&#160;units consisting of our common stock, preferred stock and warrants in one or more offerings up to an aggregate maximum offering price of&#8201; $200,000,000 (or its equivalent in other currencies). Each time we sell any of our securities, we will provide a prospectus supplement that will contain more specific information about the offering and the terms of the securities being sold. We may also add, update or change in the prospectus supplement any of the information contained in this prospectus or the documents incorporated by reference. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">This prospectus and the prospectus supplements provide you with a general description of the Company and our securities; for further information about our business and our securities, you should refer to the registration statement and the documents incorporated by reference, as described under the heading &#8220;Where You Can Find More Information.&#8221; </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">You should rely only on the information contained in this prospectus and in the applicable prospectus supplement (including in any documents incorporated by reference herein or therein). We have not authorized anyone to provide you with any different information. We are offering to sell our securities, and seeking offers to buy, only in jurisdictions where offers and sales are permitted. The information contained in this prospectus or in any prospectus supplement is accurate only as of the date of such document, and the information contained in any document incorporated herein or therein by reference is accurate only as of the date of such document incorporated by reference. Our business, financial condition, liquidity, results of operations, and prospects may have changed since those dates. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Unless otherwise indicated or unless the context requires otherwise, all references in this prospectus to &#8220;the Company,&#8221; &#8220;Novavax,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Novavax, Inc. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">1</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="t2PS">&#8203;</a><a name="t3NVX">&#8203;</a></div>
      <div style="border:1pt #000 solid;margin-top:15.3pt;min-height:703.41pt;margin-left:56pt;width:486pt;">
        <div style="margin-top:22.7pt;margin-left:14pt;width:456pt;">
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">PROSPECTUS SUMMARY </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;font-style:italic;">The following is a summary of selected information contained elsewhere or incorporated by reference in this prospectus. It does not contain all of the information that you should consider before buying our securities. You should read this entire prospectus carefully, as well as any applicable prospectus supplement, the documents incorporated by reference into this prospectus, or the applicable prospectus supplement, and any free writing prospectus we have prepared, including the material referenced under the heading &#8220;Risk Factors&#8221;. </div>
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">NOVAVAX </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Novavax is a clinical-stage biotechnology company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. Using innovative proprietary recombinant nanoparticle vaccine platform technology, we produce vaccine candidates to efficiently and effectively respond to both known and emerging disease threats. Our vaccine candidates are genetically engineered three-dimensional nanostructures that incorporate recombinant proteins critical to disease pathogenesis. Our product pipeline targets a variety of infectious diseases, with clinical vaccine candidates for respiratory syncytial virus (RSV), influenza and Ebola virus (EBOV), and preclinical programs for other infectious disease vaccine candidates. </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We are also developing immune stimulating saponin-based adjuvants through our wholly owned Swedish subsidiary, Novavax AB. Our lead adjuvant, Matrix-M&#8482;, has been shown to enhance immune responses and was well-tolerated in multiple clinical trials that we have conducted. </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Novavax was incorporated in 1987 under the laws of the State of Delaware. Our principal executive offices are located at 20 Firstfield Road, Gaithersburg, Maryland, 20878. Our telephone number is (240) 268-2000 and our website address is www.novavax.com. The information contained in, and that can be accessed through, our website is not incorporated into and does not form a part of this prospectus.</div>
        </div>
      </div>
      <div style="margin-top:3.29000000000003pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">2</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="t4RF">&#8203;</a><a name="t5UOP">&#8203;</a><a name="t6POD">&#8203;</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">RISK FACTORS </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Investing in our securities involves a high degree of risk. For a discussion of the cautionary information you should carefully consider before deciding to purchase any of our securities, please review the risk factors included in the documents incorporated by reference in this prospectus, including &#8220;Part&#160;I, Item&#160;1A&#8201;&#8212;&#8201;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2016, filed with the SEC on February&#160;27, 2017, and &#8220;Part&#160;II, Item&#160;1A - Risk Factors&#8221; in our most recent Quarterly Report on Form 10-Q for the period ended September&#160;30, 2017, filed with the SEC on November&#160;7, 2017, as well as any amendment or update to our risk factors reflected in subsequent filings with the SEC. The risks and uncertainties described in that section and in the other documents incorporated by reference are not the only risks and uncertainties we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations. If negative events occur, our business, financial condition, results of operations, and prospects would suffer. In that event, the market price of our securities could decline, and you may lose all or part of your investment. </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">USE OF PROCEEDS </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The use of proceeds from the disposition of securities covered by this prospectus will be as set forth in the applicable prospectus supplements. </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">PLAN OF DISTRIBUTION </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">General </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We may sell the securities being offered hereby from time to time in one or more of the following ways: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">through one or more underwriters; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">through dealers, who may act as agents or principal (including in a block trade in which a broker or dealer so engaged will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction); </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">directly to one or more counter-parties; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">through agents; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">through registered direct offerings; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">as part of a collaboration with a third party; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">as part of an acquisition or merger with a third party; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">through at-the-market issuances; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">in privately negotiated transactions; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">in any combination of these methods of sale. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">We will set forth in a prospectus supplement the terms of the offering, including: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the name or names of any agents, underwriters or dealers; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the terms of the securities being offered, including the purchase price and the proceeds we will receive from the sale; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">any underwriting discounts and commissions or agency fees and other items constituting underwriters&#8217; or agents&#8217; compensation; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">any options under which underwriters may purchase additional securities from us; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">any discounts or concessions allowed or reallowed or paid to dealers. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The distribution of the securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be changed, at market prices prevailing at the time of sale, at prices related to the prevailing market prices, or at negotiated prices. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">3</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Underwriters, dealers, and agents that participate in the distribution of the securities may be underwriters as defined in the Securities Act, and any discounts or commissions they receive from us and any profit on their resale of the securities may be treated as underwriting discounts and commissions under the Securities Act. We will identify in the applicable prospectus supplement any underwriters, dealers and agents and will describe their compensation. We may have agreements with underwriters, dealers and agents to indemnify them against specified civil liabilities, including liabilities under the Securities Act. Underwriters, dealers, and agents may engage in transactions with or perform services for us in the ordinary course of their businesses. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Underwriters </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If underwriters are used in the sale, we will execute an underwriting agreement with those underwriters relating to the sale of the securities. Unless otherwise set forth in the applicable prospectus supplement, the obligations of the underwriters to purchase these securities will be subject to conditions, and the underwriters will be obligated to purchase all of the securities if any are purchased. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The securities subject to an underwriting agreement will be acquired by the underwriters for their own account and may be resold by them from time to time in one or more transactions, including negotiated transactions, at a fixed public offering price or at varying prices determined at the time of sale. Underwriters may be deemed to have received compensation in the form of underwriting discounts or commissions and may also receive commissions from the purchasers of these securities for whom they may act as agent. Underwriters may sell these securities to or through dealers. These dealers may receive compensation in the form of discounts, concessions, or commissions from the underwriters and/or commissions from the purchasers for whom they may act as agent. Any public offering price and any discounts or concessions allowed or reallowed or paid to dealers may be changed from time to time. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Agents </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We may designate agents who agree to solicit purchases for the period of their appointment or to sell securities on a continuing basis. Unless the prospectus supplement provides otherwise, agents will act on a best efforts basis for the period of their appointment. Agents may receive compensation in the form of commissions, discounts, or concessions from us. Agents may also receive compensation from the purchasers of the securities. Each particular agent will receive compensation from us in amounts negotiated in connection with the sale, which might be in excess of customary commissions. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Dealers </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We may also sell securities to dealers acting as principals. If we sell our securities to a dealer as a principal, then the dealer may resell those securities to the public at varying prices to be determined by such dealer at the time of resale. The name of a dealer and the terms of the transactions will be set forth in the applicable prospectus supplement. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Direct Sales </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We may also sell securities directly to one or more purchasers, in which case underwriters or agents would not be involved in the transaction. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Institutional Purchasers </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Further, we may authorize agents, underwriters, or dealers to solicit offers by certain types of purchasers to purchase securities from us at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions to these contracts and the commissions we must pay for solicitation of these contracts in an applicable prospectus supplement. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Indemnification </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We may indemnify underwriters, dealers, or agents who participate in the distribution of securities against certain liabilities, including liabilities under the Securities Act, and agree to contribute to payments which these underwriters, dealers, or agents may be required to make.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">4</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="t7DOOCS">&#8203;</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">DESCRIPTION OF OUR CAPITAL STOCK </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Set forth below is a summary of the material terms of our capital stock. This summary is not complete. We encourage you to read our Second Amended and Restated Certificate of Incorporation, as amended through June&#160;18, 2015, and our Amended and Restated By-Laws, both of which are included as exhibits to the registration statement of which this prospectus is a part. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">General </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our authorized capital stock consists of: (1)&#160;600,000,000 shares of common stock, par value $0.01 per share, of which 323,229,390 shares were outstanding as of December&#160;21, 2017, and (2)&#160;2,000,000 shares of preferred stock, par value $0.01 per share, none of which were outstanding on December&#160;21, 2017. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Common Stock </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Holders of common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Holders of our common stock are entitled to receive ratably such dividends, if any, as may be declared by the board of directors out of funds legally available therefor, subject to any preferential dividend rights of any outstanding preferred stock. Upon the liquidation, dissolution, or winding up of the Company, the holders of our common stock are entitled to receive ratably the net assets of the Company available after the payment of all debts and liabilities and subject to the prior rights of any outstanding preferred stock. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Holders of our common stock are not entitled to pre-emptive rights or any rights of conversion. Outstanding shares of our common stock are, and the shares covered by this prospectus would be expected to be, when issued, fully paid and nonassessable. The rights, preferences and privileges of holders of our common stock are subject to, and may be adversely affected by, the rights of holders of shares of any series of preferred stock which we may designate and issue in the future. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our common stock is traded on the Nasdaq Global Select Market under the symbol &#8220;NVAX.&#8221; On December&#160;21, 2017, the closing price of our common stock as reported on the Nasdaq Global Select Market was $1.15 per share. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The registrar and transfer agent for our common stock is Computershare Limited, 250 Royall Street, Canton, MA 02021. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Preferred Stock </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The board of directors may, without further action by the stockholders, issue preferred stock in one or more series and fix the rights and preferences thereof. Our Second Amended and Restated Certificate of Incorporation grants the board of directors authority to issue preferred stock and to determine its rights and preferences without the need for further stockholder approval. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Examples of rights and preferences the board of directors may fix include dividend rates, conversion rights, voting rights, pre-emptive rights, terms of redemption (including sinking fund provisions), redemption prices, and liquidation preferences. The issuance of preferred stock, while providing desirable flexibility in connection with possible financings, could have the effect of making it more difficult for a third party to acquire, or of discouraging a third party from acquiring, a majority of our outstanding voting stock. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The terms of any particular series of preferred stock will be described in the prospectus supplement relating to the offering of shares of that particular series of preferred stock and may include, among other things: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the title and stated value; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the number of shares authorized; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.18pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the liquidation preference per share; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the purchase price; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">5</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the dividend rate, period and payment date, and method of calculation (including whether cumulative or non-cumulative), if any; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">terms and amount of any sinking fund, if applicable; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">provisions for redemption or repurchase, if applicable, and any restrictions on the ability of the Company to exercise such redemption and repurchase rights; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">conversion rights and rates, if applicable, including the conversion price and how and when it will be calculated and adjusted; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">voting rights, if any; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">preemptive rights, if any; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">restrictions on sale, transfer, and assignment, if any; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the relative ranking and preferences of the preferred stock; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">any other specific terms, rights or limitations of, or restrictions on, such preferred stock. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Provisions of our Second Amended and Restated Certificate of Incorporation, Amended and Restated By-laws, and Delaware Law </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Certain provisions of our Second Amended and Restated Certificate of Incorporation and Amended and Restated By-Laws may be deemed to have an anti-takeover effect and may prevent, delay, or defer a tender offer or takeover attempt that a stockholder may deem in his, her, or its best interest. The existence of these provisions also could limit the price that investors might be willing to pay for our securities. Such provisions include: </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:11pt;font-style:italic;">Staggered Board, Removal of Directors, and Charter Amendments relating to the Board </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our Second Amended and Restated Certificate of Incorporation and Amended and Restated By-Laws provide for the division of our board of directors into three classes, with no one class having more than one more director than any other class, serving staggered three year terms. Our Second Amended and Restated Certificate of Incorporation provides that any amendments to the charter relating to the number, classes, election, term, removal, vacancies, and related provisions with respect to the board of directors may only be made by the affirmative vote of the holders of at least 75% of the shares of capital stock issued and outstanding and entitled to vote. These provisions may have the effect of making it more difficult for a third party to acquire control of the Company, or of discouraging a third party from attempting to acquire control of the Company. </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:11pt;font-style:italic;">Authorized but Unissued Shares </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The authorized but unissued shares of our common stock and preferred stock are available for future issuance without stockholder approval, subject to any limitations imposed by the NASDAQ Stock Market. These additional shares may be utilized for a variety of corporate purposes. In particular, our board of directors could issue shares of preferred stock that could, depending on the terms of the series, impede the completion of a takeover effort. Our board of directors may determine that the issuance of such shares of preferred stock is in the best interest of the Company and our stockholders. Such issuance could discourage a potential acquiror from making an unsolicited acquisition attempt through which such acquiror may be able to change the composition of the board, including a tender offer or other transaction a majority of our stockholders might believe to be in their best interest or in which stockholders might receive a substantial premium for their stock over the then-current market price. </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:11pt;font-style:italic;">Advance Notice Requirements for Stockholder Proposals and Director Nominations </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our Amended and Restated By-Laws provide that a stockholder seeking to bring business before an annual meeting of stockholders, or to nominate candidates for election as directors, must provide timely notice of such stockholder&#8217;s intention in writing. To be timely, a stockholder nominating individuals for election to the Board of Directors or proposing business must provide advanced notice to the Company not </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">6</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">less than 60&#160;days nor more than 90&#160;days prior to the anniversary date of the prior year&#8217;s annual meeting of stockholders or, in the case of any special meeting, not less than 60&#160;days nor more than 90&#160;days prior to the special meeting, unless, in the case of annual meeting, such meeting occurs more than 30&#160;days before or after such anniversary date, or, in the case of a special meeting, such meeting occurs less than 100&#160;days after notice or public disclosure of the date of the special meeting is given or made, in which cases notice will be timely if received not later than the close of business on the tenth day after the day on which notice or public announcement of the date of such meeting was made. </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:11pt;font-style:italic;">Limits on Ability of Stockholders to Act by Written Consent </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our Second Amended and Restated Certificate of Incorporation provides that our stockholders may not act by written consent. In addition, our Second Amended and Restated Certificate of Incorporation requires that special meetings of stockholders be called only by our board of directors, our chief executive officer, or our president if there is no chief executive officer. Further, business transacted at any special meeting of stockholders is limited to matters relating to the purpose or purposes stated in the notice of meeting. This limit on the ability of our stockholders to act by written consent or to call a special meeting may lengthen the amount of time required to take stockholder proposed actions. </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:11pt;font-style:italic;">Section&#160;203 of the General Corporation Law of the State of Delaware </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We are subject to Section&#160;203 of the Delaware General Corporation Law. This statute regulating corporate takeovers prohibits a Delaware corporation from engaging in any business combination with an interested stockholder for three&#160;years following the date that the stockholder became an interested stockholder, unless: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">upon completion of the transaction that resulted in the interested stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (1)&#160;shares owned by persons who are directors and also officers, and (2)&#160;shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 <font style=" position:relative; bottom:2.66pt;font-size:7pt;">2</font>&#8725;<font style="font-size:7pt;">3</font>% of the outstanding voting stock that is not owned by the interested stockholder. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Generally, a business combination includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. An interested stockholder is any person who, together with such person&#8217;s affiliates and associates (1)&#160;owns 15% or more of a corporation&#8217;s voting securities or (2)&#160;is an affiliate or associate of a corporation and was the owner of 15% or more of the corporation&#8217;s voting securities at any time within the three year period immediately preceding a business combination governed by Section&#160;203. We expect the existence of this provision to have an anti-takeover effect with respect to transactions our board of directors does not approve.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">7</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="t8DOW">&#8203;</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">DESCRIPTION OF WARRANTS </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">This description only summarizes the terms of warrants that we may offer under this prospectus and related warrant agreements and certificates. You should refer to the warrant agreement, including the form of warrant certificate representing the warrants, relating to the specific warrants being offered for complete terms, which would be provided at the time of such offering. Such warrant agreement, together with the warrant certificate, would be filed with the SEC in connection with the offering of the specific warrants. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We may issue warrants for the purchase of common or preferred stock. Warrants may be issued independently or together with common or preferred stock, and may be attached to or separate from any offered securities. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We may evidence a series of warrants by warrant certificates that we issue under a separate warrant agreement. We may enter into a warrant agreement with a warrant agent and, if so, we will indicate the name and address of the warrant agent in the applicable prospectus supplement relating to the particular series of warrants. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The particular terms of any series of warrants will be described in the prospectus supplement relating to the series. Those terms may include: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the title of such warrants; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the aggregate number of such warrants; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the price or prices at which such warrants will be issued; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the currency or currencies (including composite currencies) in which the price of such warrants may be payable; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the terms of the securities issuable upon exercise of such warrants and the procedures and conditions relating to the exercise of such warrants; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the price at which the securities issuable upon exercise of such warrants may be acquired; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the dates on which the right to exercise such warrants will commence and expire; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">any provisions for adjustment of the number or amount of securities receivable upon exercise of the warrants or the exercise price of the warrants; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">if applicable, the minimum or maximum amount of such warrants that may be exercised at any one time; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">if applicable, the designation and terms of the securities with which such warrants are issued and the number of such warrants issued with each such security or principal amount of such security; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">if applicable, the date on and after which such warrants and the related securities will be separately transferable; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">information with respect to book-entry procedures, if any; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">any other terms of such warrants, including terms, procedures and limitations relating to the exchange or exercise of such warrants. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Each warrant will entitle its holder to purchase the number of shares of common or preferred stock at the exercise price set forth in, or calculable as set forth in, the applicable prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any time up to the expiration date set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void. We will specify the place or places where, and the manner in which, warrants may be exercised in the applicable prospectus supplement. We will set forth on the reverse side of the applicable certificate and in the applicable prospectus supplement the information that the holder of the warrant will be required to deliver upon exercise. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Prior to the exercise of any warrants to purchase preferred stock or common stock, holders of the warrants will not have any of the rights of holders of the preferred stock or common stock purchasable upon exercise, including the right to vote or to receive any payments of dividends.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">8</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="t9DOOU">&#8203;</a><a name="t10DP">&#8203;</a><a name="t11LM">&#8203;</a><a name="t12EXP">&#8203;</a><a name="t13WYCFMI">&#8203;</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">DESCRIPTION OF OUR UNITS </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We may issue&#160;units comprised of two or more of the other securities described in this prospectus in any combination. Each unit will be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included security. The&#160;units may be issued under unit agreements to be entered into between us and a bank or trust company, as unit agent, as detailed in the prospectus supplement relating to&#160;units being offered. The prospectus supplement will describe: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the designation and terms of the&#160;units and of the securities comprising the&#160;units, including whether and under what circumstances the securities comprising the&#160;units may be held or transferred separately; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a description of the terms of any unit agreement governing the&#160;units; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a description of the provisions for the payment, settlement, transfer, or exchange of the&#160;units; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">whether the&#160;units will be issued in fully registered or global form. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">DIVIDEND POLICY </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have never paid cash dividends on our common stock. We currently anticipate that we will retain any earnings for use in the development of our business and do not anticipate paying any cash dividends in the foreseeable future. </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">LEGAL MATTERS </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Unless the applicable prospectus supplement indicates otherwise, our counsel Ropes &amp; Gray LLP, Boston Massachusetts, will pass upon the validity of the securities offered by this prospectus. </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">EXPERTS </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The consolidated financial statements of Novavax, Inc. appearing in Novavax Inc.&#8217;s Annual Report (Form 10-K) for the year ended December&#160;31, 2016, and the effectiveness of Novavax Inc.&#8217;s internal control over financial reporting as of December&#160;31, 2016 have been audited by Ernst &amp; Young LLP, independent registered public accounting firm, as set forth in their reports thereon, included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such reports given on the authority of such firm as experts in accounting and auditing. </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">WHERE YOU CAN FIND MORE INFORMATION </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have filed a registration statement on Form S-3 with the SEC registering the offer and sale of our securities offered by this prospectus. This prospectus does not include all of the information contained in the registration statement. You should refer to the registration statement, its exhibits, and the information incorporated in this prospectus for additional information. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy any materials that we file with the SEC at its Public Reference Room, 100 F Street, N.E., Washington, D.C. 20549. You may call the SEC at 1-800-SEC-0330 for further information on the operation of the Public Reference Room. Our SEC filings are also available to the public from the SEC&#8217;s website at http://www.sec.gov.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">9</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="t14IOCIBR">&#8203;</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The SEC&#8217;s rules allow us to &#8220;incorporate by reference&#8221; information we have filed with the SEC, which means that we can disclose important information by referring you to those documents. The information incorporated by reference is a part of this prospectus, and information that we file later with the SEC will automatically update and supersede the information included and/or incorporated by reference in this prospectus. We incorporate by reference into this prospectus the documents listed below and any future filings made by us with the SEC under Sections&#160;13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934 (other than, in each case, any document or portion of a document that is deemed not to be filed) after the initial filing of the registration statement that contains this prospectus and prior to the time that we sell all of the securities offered by this prospectus: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our Annual Report on Form 10-K for the year ended December&#160;31, 2016, filed with the SEC on February&#160;27, 2017; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our Quarterly Reports on Form 10-Q for the quarters ended March&#160;31, 2017, filed with the SEC on May&#160;8, 2017, June&#160;30, 2017, filed with the SEC on August&#160;8, 2017 and September&#160;30, 2017, filed with the SEC on November&#160;7, 2017; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our Current Reports on Form 8-K, filed with the SEC on June&#160;16, 2017, July&#160;26, 2017, October&#160;13, 2017, November&#160;7, 2017 and December&#160;29, 2017; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the description of our common stock contained in the Registration Statement on Form 10 filed with the SEC on September&#160;14, 1995, including any amendments or reports filed for the purpose of updating such description. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">You may obtain documents incorporated by reference into this prospectus at no cost by requesting them in writing or telephoning us at the following address: </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;">Investor Relations <br >Novavax, Inc. <br >20 Firstfield Road <br >Gaithersburg, MD 20878 <br >(240) 268-2000 <br >ir@novavax.com </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">These filings are also made available, free of charge, on our website at www.novavax.com. The information contained in, and that can be accessed through, our website is not incorporated into and does not form a part of this prospectus. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">10</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">PART II</div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">INFORMATION NOT REQUIRED IN PROSPECTUS </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Item&#160;14.&nbsp;&nbsp;&nbsp;Other Expenses of Issuance and Distribution. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following table sets forth all fees and expenses payable by the registrant in connection with the issuance and distribution of the securities being registered hereby (other than any underwriting discounts and commissions). All amounts are estimated. </div>
        <table style="width:416pt;height:100.5pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:371.29pt;text-align:left;">
              <div style="white-space:nowrap;">SEC registration fee </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">24,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:371.29pt;text-align:left;">
              <div style="white-space:nowrap;">Printing and engraving fees </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">5,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:371.29pt;text-align:left;">
              <div style="white-space:nowrap;">Legal fees and expenses </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">50,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:371.29pt;text-align:left;">
              <div style="white-space:nowrap;">Accounting fees and expenses </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">20,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:371.29pt;text-align:left;">
              <div style="white-space:nowrap;">Transfer Agent and Registrar Fees </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:371.29pt;text-align:left;">
              <div style="white-space:nowrap;">Miscellaneous </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:371.29pt;text-align:left;">
              <div style="margin-left:10pt;">Total </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:14.49pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:11.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">*<br ></div>
        <div style=" float:left; margin-top:11.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:435.5pt;">These fees are calculated based on the number of issuances and the amount of securities offered and accordingly cannot be estimated at this time. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Item&#160;15.&nbsp;&nbsp;&nbsp;Indemnification of Directors and Officers. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Section&#160;102 of the Delaware General Corporation Law permits a corporation to eliminate the personal liability of its directors or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his or her duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. Our Second Amended and Restated Certificate of Incorporation provides that no director shall be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability, except to the extent that the Delaware General Corporation Law prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Section&#160;145 of the Delaware General Corporation Law provides that a corporation has the power to indemnify a director, officer, employee or agent of the corporation and certain other persons serving at the request of the corporation in related capacities against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlements actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he or she is party or is threatened to be made a party by reason of such position, if such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnification for such expenses which the Court of Chancery or such other court shall deem proper. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our Second Amended and Restated Certificate of Incorporation provides that we will indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding whether civil, criminal, administrative or investigative (other than an action by or in the right of us) by reason of the fact that he or she is or was, or has agreed to become, our director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (all such persons being referred to as an &#8220;Indemnitee&#8221;), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&#8217; fees), judgments, fines and amounts paid </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">II-1</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">in settlement actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our Second Amended and Restated Certificate of Incorporation also provides that we will indemnify any Indemnitee who was or is a party to an action or suit by or in the right of us to procure a judgment in our favor by reason of the fact that the Indemnitee is or was, or has agreed to become, our director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer or trustee or, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise, or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&#8217; fees) and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, except that no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to us, unless and only to the extent that the Court of Chancery of Delaware determines that, despite such adjudication but in view of all of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding the foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by us against all expenses (including attorneys&#8217; fees) actually and reasonably incurred by him or her or on his or her behalf in connection therewith. If we do not assume the defense, expenses must be advanced to an Indemnitee under certain circumstances. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have entered into indemnification agreements with our directors and certain of our officers, in addition to the indemnification provided for in our Second Amended and Restated Certificate of Incorporation and Amended and Restated By-Laws, and intend to enter into indemnification agreements with any new directors and executive officers in the future. We have purchased and intend to maintain insurance on behalf of any person who is or was a director or officer against any loss arising from any claim asserted against him or her and incurred by him or her in any such capacity, subject to certain exclusions. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">Also see &#8220;Undertakings.&#8221; </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Item&#160;16.&nbsp;&nbsp;&nbsp;Exhibits. </div>
        <table style="width:456pt;height:230.5pt;margin-top:7pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap;">Exhibit&#160;No. </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:405pt;text-align:center;">
              <div style="white-space:nowrap; text-align:center;">Description </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt;padding-left:0pt;width:0pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1000694/000114420415047742/v416489_ex3-1.htm">&#8203;</a></td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; "><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1000694/000114420415047742/v416489_ex3-1.htm">&#8203;</a></td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1000694/000114420415047742/v416489_ex3-1.htm">3.1</a></td>
            <td style="padding:0pt;padding-left:21.29pt;width:0pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1000694/000114420415047742/v416489_ex3-1.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1000694/000114420415047742/v416489_ex3-1.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1000694/000114420415047742/v416489_ex3-1.htm">&#8203;</a></td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:405pt;white-space:normal;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1000694/000114420415047742/v416489_ex3-1.htm">Second Amended and Restated Certificate of Incorporation of the Registrant dated June&#160;18, 2015 (Incorporated by reference to Exhibit&#160;3.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June&#160;30, 2015, filed on August&#160;10, 2015). </a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1000694/000114420415047742/v416489_ex3-1.htm">&#8203;</a></td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt;padding-left:0pt;width:0pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1000694/000114420413014545/v335539_ex3-2.htm">&#8203;</a></td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; "><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1000694/000114420413014545/v335539_ex3-2.htm">&#8203;</a></td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1000694/000114420413014545/v335539_ex3-2.htm">3.2</a></td>
            <td style="padding:0pt;padding-left:21.29pt;width:0pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1000694/000114420413014545/v335539_ex3-2.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1000694/000114420413014545/v335539_ex3-2.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1000694/000114420413014545/v335539_ex3-2.htm">&#8203;</a></td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:405pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1000694/000114420413014545/v335539_ex3-2.htm">Amended and Restated By-Laws of the Registrant (Incorporated by reference to Exhibit&#160;3.2 to <br >the Registrant&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2012, filed on <br >March&#160;12, 2013). </a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1000694/000114420413014545/v335539_ex3-2.htm">&#8203;</a></td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.1</td>
            <td style="padding:0pt;padding-left:21.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:405pt;white-space:normal;">Specimen stock certificate for shares of common stock, par value $.01 per share (Incorporated by reference to Exhibit&#160;4.1 to the Company&#8217;s Registration Statement on Form 10, File No. 0-26770, filed September&#160;14, 1995) </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.3<font style="position:absolute;">&#8224;</font></td>
            <td style="padding:0pt;padding-left:21.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:405pt;">Certificate of Designation of Preferred Stock. </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.4<font style="position:absolute;">&#8224;</font></td>
            <td style="padding:0pt;padding-left:21.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:405pt;">Form of Warrant Agreement and Warrant Certificate. </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.5<font style="position:absolute;">&#8224;</font></td>
            <td style="padding:0pt;padding-left:21.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:405pt;">Form of Unit Agreement. </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt;padding-left:0pt;width:0pt;"><a style="-sec-extract:exhibit" href="tv482183_ex5-1.htm">&#8203;</a></td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; "><a style="-sec-extract:exhibit" href="tv482183_ex5-1.htm">&#8203;</a></td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;"><a style="-sec-extract:exhibit" href="tv482183_ex5-1.htm">5.1<font style="position:absolute;">*</font></a></td>
            <td style="padding:0pt;padding-left:21.29pt;width:0pt;"><a style="-sec-extract:exhibit" href="tv482183_ex5-1.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="tv482183_ex5-1.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="tv482183_ex5-1.htm">&#8203;</a></td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:405pt;"><a style="-sec-extract:exhibit" href="tv482183_ex5-1.htm">Opinion of Ropes &amp; Gray LLP. </a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="tv482183_ex5-1.htm">&#8203;</a></td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt;padding-left:0pt;width:0pt;"><a style="-sec-extract:exhibit" href="tv482183_ex23-1.htm">&#8203;</a></td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; "><a style="-sec-extract:exhibit" href="tv482183_ex23-1.htm">&#8203;</a></td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;"><a style="-sec-extract:exhibit" href="tv482183_ex23-1.htm">23.1<font style="position:absolute;">*</font></a></td>
            <td style="padding:0pt;padding-left:21.29pt;width:0pt;"><a style="-sec-extract:exhibit" href="tv482183_ex23-1.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="tv482183_ex23-1.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="tv482183_ex23-1.htm">&#8203;</a></td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:405pt;"><a style="-sec-extract:exhibit" href="tv482183_ex23-1.htm">Consent of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm. </a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="tv482183_ex23-1.htm">&#8203;</a></td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt;padding-left:0pt;width:0pt;"><a style="-sec-extract:exhibit" href="tv482183_ex5-1.htm">&#8203;</a></td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; "><a style="-sec-extract:exhibit" href="tv482183_ex5-1.htm">&#8203;</a></td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;"><a style="-sec-extract:exhibit" href="tv482183_ex5-1.htm">23.2<font style="position:absolute;">*</font></a></td>
            <td style="padding:0pt;padding-left:21.29pt;width:0pt;"><a style="-sec-extract:exhibit" href="tv482183_ex5-1.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="tv482183_ex5-1.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="tv482183_ex5-1.htm">&#8203;</a></td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:405pt;"><a style="-sec-extract:exhibit" href="tv482183_ex5-1.htm">Consent of Ropes &amp; Gray LLP (included in Exhibit&#160;5.1). </a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="tv482183_ex5-1.htm">&#8203;</a></td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt;padding-left:0pt;width:0pt;"><a style="-sec-extract:exhibit" href="#tPOA">&#8203;</a></td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; "><a style="-sec-extract:exhibit" href="#tPOA">&#8203;</a></td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;"><a style="-sec-extract:exhibit" href="#tPOA">24.1<font style="position:absolute;">*</font></a></td>
            <td style="padding:0pt;padding-left:21.29pt;width:0pt;"><a style="-sec-extract:exhibit" href="#tPOA">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="#tPOA">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="#tPOA">&#8203;</a></td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:405pt;"><a style="-sec-extract:exhibit" href="#tPOA">Powers of Attorney (included on the signature page to this Registration Statement).</a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="#tPOA">&#8203;</a></td>
          </tr>
        </table>
        <div style="margin-top:12.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:5.02pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">*<br ></div>
        <div style=" float:left; margin-top:5.02pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:435.5pt;">Filed herewith. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.01pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8224;<br ></div>
        <div style=" float:left; margin-top:3.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:435.5pt;">To be filed if necessary, subsequent to the effectiveness of this registration statement by an amendment to this registration statement or incorporated by reference pursuant to a Current Report on Form 8-K in connection with the offering of securities. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">II-2</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Item&#160;17.&nbsp;&nbsp;&nbsp;Undertakings. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">The undersigned registrant hereby undertakes: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(i)<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:395.5pt;">To include any prospectus required by Section&#160;10(a)(3) of the Securities Act of 1933; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(ii)<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:395.5pt;">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule&#160;424(b) if, in the aggregate, the changes in volume and price represent no more than a 20&#160;percent change in the maximum aggregate offering price set forth in the &#8216;&#8216;Calculation of Registration Fee&#8217;&#8217; table in the effective registration statement; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(iii)<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:395.5pt;">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:60pt; margin-top:6pt; width:396pt; line-height:12pt;font-style:italic;">provided, however<font style="font-style:normal;">, that: </font></div>
        <div style=" float:left; margin-left:60pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(A)<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:375.5pt;">Paragraphs (1)(i) and (1)(ii) of this section do not apply if the registration statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:60pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(B)<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:375.5pt;">Paragraphs (1)(i), (1)(ii) and (1)(iii) of this section do not apply if the registration statement is on Form S-3 or Form F-3 and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule&#160;424(b) that is part of the registration statement. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:60pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(C)<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:375.5pt;"><font style="font-style:italic;">Provided further, however,</font> that paragraphs (1)(i) and (1)(ii) do not apply if the registration statement is for an offering of asset-backed securities on Form S-1 or Form S-3, and the information required to be included in a post-effective amendment is provided pursuant to Item&#160;1100(c) of Regulation&#160;AB. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <font style="font-style:italic;">bona fide</font> offering thereof. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(3)<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(4)<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser: </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(i)<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:395.5pt;">If the registrant is relying on Rule&#160;430B: </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:60pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(A)<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:375.5pt;">Each prospectus filed by the registrant pursuant to Rule&#160;424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:60pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(B)<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:375.5pt;">Each prospectus required to be filed pursuant to Rule&#160;424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule&#160;430B relating to an offering made </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">II-3</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-left:80pt; width:376pt; line-height:12pt;">pursuant to Rule&#160;415(a)(1)(i), (vii) or (x)&#160;for the purpose of providing the information required by Section&#160;10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule&#160;430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial <font style="font-style:italic;">bona fide</font> offering thereof. <font style="font-style:italic;">Provided, however, </font>that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date; or </div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(ii)<br ></div>
        <div style=" float:left; margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:395.5pt;">If the registrant is subject to Rule&#160;430C, each prospectus filed pursuant to Rule&#160;424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule&#160;430B or other than prospectuses filed in reliance on Rule&#160;430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. <font style="font-style:italic;">Provided, however,</font> that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(5)<br ></div>
        <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(i)<br ></div>
        <div style=" float:left; margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:395.5pt;">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule&#160;424; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(ii)<br ></div>
        <div style=" float:left; margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:395.5pt;">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(iii)<br ></div>
        <div style=" float:left; margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:395.5pt;">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(iv)<br ></div>
        <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:395.5pt;">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(6)<br ></div>
        <div style=" float:left; margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">That, for purposes of determining any liability under the Securities Act of 1933 each filing of the registrant&#8217;s annual report pursuant to Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to Section&#160;15(d) of the Securities Exchange Act of 1934, as amended) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <font style="font-style:italic;">bona fide</font> offering thereof.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">II-4</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(7)<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">That, for purposes determining any liability under the Securities Act of 1933: </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(i)<br ></div>
        <div style=" float:left; margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:395.5pt;">the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule&#160;430A and contained in a form of prospectus filed by the registrant pursuant to Rule&#160;424(b)(1) or (4)&#160;or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(ii)<br ></div>
        <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:395.5pt;">each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933, and will be governed by the final adjudication of such issue.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">II-5</div>
      </div>
      <hr >
    </div>
    <div style=" width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPOA">&#8203;</a></div>
      <div style="margin-top:46pt;margin-bottom:49.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">SIGNATURES </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Pursuant to the requirements of the Securities Act of 1933, as amended, Novavax, Inc. certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Gaithersburg, State of Maryland on the 29th day of December&#160;2017. </div>
        <table style="width:228pt;margin-left:228pt;margin-top:8.00000000000001pt;border-collapse: collapse;">
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:0pt;" colspan="4">NOVAVAX, INC. </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:10.167pt 0pt 0.5pt 0pt; width:22.5pt;">By: </td>
            <td style="padding:0pt; width:1.5pt;">&#8203;</td>
            <td style="padding:0pt; width:1.5pt;">&#8203;</td>
            <td style="padding:10.167pt 0pt 0.5pt 0pt; width:202.5pt;white-space:normal;">
              <div>/s/ Stanley C. Erck</div>
              <div style="margin-top:2.5pt;">
                <div style="margin-left: 0pt; width: 202.5pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">Stanley C. Erck <br >President, Chief Executive Officer, Interim Chief Financial Officer and Director</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:22.99pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">SIGNATURES AND POWERS OF ATTORNEY </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">KNOW ALL MEN BY THESE PRESENTS, that we, the undersigned officers and directors of Novavax, Inc., a Delaware corporation, hereby severally constitute Stanley C. Erck, and John A. Herrmann III, and each of them singly, our true and lawful attorney with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement filed herewith and any and all amendments or supplements thereto (including registration statements filed pursuant to Rule&#160;462(b)), and generally to do all such things in our names and in our capacities as officers and directors to enable Novavax, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated. </div>
        <table style="width:456pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:147pt;text-align:left;">
              <div style="white-space:nowrap;">NAME </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:201pt;">
              <div style="white-space:nowrap; text-align:center;">TITLE </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:84pt;">
              <div style="white-space:nowrap; text-align:center;">DATE </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:1.917pt 0pt 2.833pt 0pt; width:147pt;">
              <div>/s/ Stanley C. Erck</div>
              <div style="margin-top:2.5pt;">
                <div style="margin-left: 0pt; width: 147pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">Stanley C. Erck </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 2.833pt 0pt; width:201pt;white-space:normal;">President, Chief Executive Officer, Interim Chief Financial Officer and Director <br >(Principal Executive Officer and Principal Financial and Accounting Officer) <br ></td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 2.833pt 0pt; width:84pt;">
              <div style="white-space:nowrap;">December&#160;29, 2017 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4.167pt 0pt 4.833pt 0pt; width:147pt;">
              <div>/s/ James F. Young</div>
              <div style="margin-top:2.5pt;">
                <div style="margin-left: 0pt; width: 147pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">James F. Young </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 4.833pt 0pt; width:201pt;">Chairman of the Board of Directors </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 4.833pt 0pt; width:84pt;">
              <div style="white-space:nowrap;">December&#160;29, 2017 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4.167pt 0pt 4.833pt 0pt; width:147pt;">
              <div>/s/ Richard H. Douglas</div>
              <div style="margin-top:2.5pt;">
                <div style="margin-left: 0pt; width: 147pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">Richard H. Douglas </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 4.833pt 0pt; width:201pt;">Director </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 4.833pt 0pt; width:84pt;">
              <div style="white-space:nowrap;">December&#160;29, 2017 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4.167pt 0pt 4.833pt 0pt; width:147pt;">
              <div>/s/ Gary C. Evans</div>
              <div style="margin-top:2.5pt;">
                <div style="margin-left: 0pt; width: 147pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">Gary C. Evans </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 4.833pt 0pt; width:201pt;">Director </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 4.833pt 0pt; width:84pt;">
              <div style="white-space:nowrap;">December&#160;29, 2017 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4.167pt 0pt 4.833pt 0pt; width:147pt;">
              <div>/s/ Michael A. McManus</div>
              <div style="margin-top:2.5pt;">
                <div style="margin-left: 0pt; width: 147pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">Michael A. McManus </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 4.833pt 0pt; width:201pt;">Director </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 4.833pt 0pt; width:84pt;">
              <div style="white-space:nowrap;">December&#160;29, 2017 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4.167pt 0pt 4.833pt 0pt; width:147pt;">
              <div>/s/ Rajiv I. Modi</div>
              <div style="margin-top:2.5pt;">
                <div style="margin-left: 0pt; width: 147pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">Rajiv I. Modi </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 4.833pt 0pt; width:201pt;">Director </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 4.833pt 0pt; width:84pt;">
              <div style="white-space:nowrap;">December&#160;29, 2017</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <hr >
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>tv482183_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.15pt 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.15pt 0pt 0; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.15pt 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD NOWRAP STYLE="width: 5%"><IMG SRC="image_001.jpg" ALT="Logo" STYLE="width: 62px; height: 79px">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="width: 95%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">ROPES
                           &amp; GRAY LLP</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">PRUDENTIAL TOWER</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">800 BOYLSTON STREET</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">BOSTON, MA 02199-3600</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">WWW.ROPESGRAY.COM</FONT></P></TD></TR>
</TABLE>
<P STYLE="margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.15pt 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.15pt 0pt 0; text-align: center">December 29, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.15pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Novavax, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">20 Firstfield Road<BR>
Gaithersburg, MD 20878</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Re: Registration of Securities by Novavax, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.15in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.15in 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have acted as counsel to Novavax, Inc.,
a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), in connection with the registration statement on Form S-3 (the &ldquo;<U>Registration
Statement</U>&rdquo;) filed on or about the date hereof by the Company with the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;)
under the Securities Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;), relating to the registration under the
Securities Act, and the proposed issuance and sale from time to time pursuant to Rule&nbsp;415 under the Securities Act, of up
to $200,000,000 of the following securities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(i) shares of the common stock of the Company,
$0.01 par value per share (&ldquo;<U>Common Stock</U>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(ii) shares of preferred stock of the Company,
$0.01 par value per share (&ldquo;<U>Preferred Stock</U>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(iii) warrants representing the right to
acquire, upon exercise, a number of shares of Common Stock or Preferred Stock (&ldquo;<U>Warrants</U>&rdquo;); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(iv) units of the Company consisting of
two or more of any combination of Common Stock, Preferred Stock or Warrants (the &ldquo;<U>Units</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Common Stock, the Preferred Stock, the
Warrants and the Units are referred to herein collectively as the &ldquo;<U>Securities</U>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In connection with this opinion letter,
we have examined such certificates, documents and records and have made such investigation of fact and such examination of law
as we have deemed appropriate in order to enable us to render the opinions set forth herein. In conducting such investigation,
we have relied, without independent verification, upon certificates of officers of the Company, public officials and other persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The opinions expressed below are limited
to the Delaware General Corporation Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Based upon and subject to the foregoing
and the assumptions, qualifications and limitations set forth below, we are of the opinion that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">Novavax, Inc.</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;When
(i) the issuance and sale of any shares of Common Stock have been duly authorized by all necessary corporate action of the Company
and (ii) such shares have been issued and delivered against payment of the purchase price therefor (in an amount in excess of the
par value thereof) in accordance with the applicable purchase, underwriting or other agreement, and as contemplated by the Registration
Statement, such shares of Common Stock will be validly issued, fully paid and nonassessable. </FONT>The Common Stock covered in
the opinion in this paragraph includes any shares of Common Stock that may be issued upon exercise, conversion or exchange pursuant
to the terms of any other Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;When
(i) the terms of any Preferred Stock of a particular series and their issuance and sale have been duly authorized by all necessary
corporate action of the Company, (ii) a certificate of designations with respect to such series of Preferred Stock has been duly
adopted by the Company and filed with the Secretary of State of the State of Delaware and (iii)&nbsp;such shares of Preferred Stock
have been issued and delivered against payment of the purchase price therefor (in an amount in excess of the par value thereof)
in accordance with the applicable purchase, underwriting or other agreement, and as contemplated by the Registration Statement,
such shares of Preferred Stock will be validly issued, fully paid and nonassessable. The Preferred Stock covered in the opinion
in this paragraph includes any shares of Preferred Stock that may be issued upon exercise, conversion or exchange pursuant to the
terms of any other Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
When (i) the terms of any Warrants and their issuance and sale have been duly authorized by all necessary corporate action of the
Company and (ii) such Warrants have been duly executed, countersigned and delivered in accordance with the applicable warrant agreement
and against payment of the purchase price therefor in accordance with the applicable purchase, underwriting or other agreement,
and as contemplated by the Registration Statement, such Warrants will constitute valid and binding obligations of the Company enforceable
against the Company in accordance with their terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;When
(i) the terms of any Units (including the terms of the component Securities) and their sale have been duly authorized by all necessary
corporate action of the Company and (ii) any Unit agreements have been duly executed (if the Units are represented by a separate
instrument) and delivered in accordance with the applicable purchase, underwriting or other agreement, and as contemplated by the
Registration Statement, such Units will constitute valid and binding obligations of the Company enforceable against the Company
in accordance with their respective terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In rendering the opinions set forth above,
we have assumed that (i)&nbsp;the Registration Statement will have become effective under the Securities Act, a prospectus supplement
will have been prepared and filed with the Commission describing the Securities offered thereby and such Securities will have been
issued and sold in accordance with the terms of such prospectus supplement; (ii)&nbsp;a definitive purchase, underwriting or similar
agreement and any applicable warrant agreement, pursuant to which such Securities may be issued, will have been duly authorized,
executed and delivered by the Company and the other parties thereto, and the specific terms of such Securities will have been duly
established in conformity with the applicable agreement and the certificate of incorporation and bylaws of the Company (if applicable);
(iii) at the time of the issuance of any Securities, the Company will be a validly existing corporation under the law of its jurisdiction
of incorporation; (iv)&nbsp;the number of shares of Common Stock issued pursuant to the Registration Statement, together with the
number of shares outstanding or reserved at the time of issuance, will not exceed the respective number of shares authorized by
the Company&rsquo;s certificate of incorporation in effect at the time of such issuance; and (v) all the foregoing actions to be
taken by the Company will have been taken so as not to violate any applicable law and so as to comply with any requirement or restriction
imposed by any court or governmental or regulatory body having jurisdiction over the Company or any of its property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">Novavax, Inc.</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We hereby consent to the filing of this
opinion letter as an exhibit to the Registration Statement and to the use of our name therein and in the related prospectus under
the caption &ldquo;Legal Matters.&rdquo; In giving such consent, we do not thereby admit that we are in the category of persons
whose consent is required under Section&nbsp;7 of the Securities Act or the rules and regulations of the Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%">Very truly yours,</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>/s/ Ropes &amp; Gray LLP</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Ropes&nbsp;&amp; Gray LLP</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>tv482183_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consent of Independent Registered Public
Accounting Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We consent to the reference to our firm
under the caption &quot;Experts&quot; in the Registration Statement (Form S-3) and related Prospectus of Novavax, Inc. for the
registration of its common stock and to the incorporation by reference therein of our reports dated February 27, 2017, with respect
to the consolidated financial statements of Novavax Inc., and the effectiveness of internal control over financial reporting of
Novavax, Inc., included in its Annual Report (Form 10-K) for the year ended December 31, 2016, filed with the Securities and Exchange
Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Ernst &amp; Young LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Baltimore, MD</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">December 29, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #1F497D">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #1F497D"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #1F497D">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0; text-align: right"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !/ #X# 2(  A$! Q$!_\0
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M$ DX-10Z+8ZY\1O$$>I0&=(8K<QJ78!25YZ$>E7]4_Y*AH7_ %YW']*31/\
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9.1R",BM#P5&\/@[3$D7:ZPX(STY- (__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>lg_novavax.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lg_novavax.jpg
M_]C_X  02D9)1@ ! 0$ KP"O  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$( %4"(P,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M:#>32636UN- O-?O=1,BZ=:F+^27_B(*_P""H'_18_!G_AG/AE_\S=?Z WQ
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MM\.O":PSZA8B_M_#BW5B_BG6KK0_!<%[9LEY93^(X[ZWDA:U,\7]D]?SA?\
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M-R,K#(()_N/_ (AQX?WM_J7PO?>W]C8*]EN[6O975]-+J^Z/X2_XB3XAVO\
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M*;DY+!9C"$L10:O&C5^LX.4N;#T^>Q7\;'_!3+_@OU\</"?[2FO?"_\ 8?\
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M*$*5*G"$4HQA3ITZ<(1BDHPA&*244?D1_P %K/VUO^&-_P!BWQ:?#&K?V?\
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MA\+7/BJQM2IU23=_H_U_G=XU<$_ZF\9XJ6%I>SR;/_:YQE7+'EI476K2_M#
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MIS5N7%8VA:2G!6_*"OIK]C?]FOQ+^UY^TS\'_P!GKPRM[%)\1/%]A8:_J]C
ML\OAGP58EM4\;^*BLB/!_P 4]X5LM5U.".XVQ7=Y;VUCN\VZC5OF6OH?]FC]
MJSX\?L?>/KWXH_L[^-++P#X]OO#M]X4F\1W'@GP!XVN8="U.\T^^O[33[;X@
M^%O%=AI4UW/I=FDVHZ9:6FIO:+/8&\^PWEY;7']_YQ'-)Y5F4,DEA89O4P6)
MIY94QLYT\)2QM2E*GAZ^(E3HUZGLZ$ZGMW&-&HYRH4Z;CRSFU_GKDTLKAFV6
MSSR.*GD]/'8:IF=/!0A4Q=; TZL*F(H8>-6MAZ?M*].G]74I5J:A&O4J*7-3
M@G_J9>"?!WAOX=^#?"?@#P=I=OHGA+P1X;T3PEX8T>U7;;:7X?\ #NFVVD:/
MI\ _YY6>GVEO A/)$8+$DDUT]?YR_P#P_B_X*M_]'4_^8._9O_\ G/T?\/XO
M^"K?_1U/_F#OV;__ )S]?Q;/Z-/'U6<ZM3..%ZE2I.=2I4GC\VE.I4J3G4J3
MG*64.4ISG.<YRDW*4IRDVW)M_P!MT_I.^'U*G"E2R;BJG3I0A2ITX9?E$(4Z
M=.$*=.G",<X48PA3IPA",4HQA",4DHI+M/\ @O'^Q^W[+W[<?BCQCX=TIK'X
M7_M+17WQ@\)20QE;&R\6WMZ(OBMX;B?9%&MQ8^+KC_A*4L[:);73="\;>'[&
M)W:&0)^*=?:G[4G_  4._:__ &TM \+>&?VF?BO:?$S2/!.L7FN^%HW^&GPD
M\(WVC:EJ-D-/U![;6? ?@/POK+VE_:I M[IEQ?S:9=36=A=3V<EUI]C-;_%=
M?U[P9@,\RKA?)LKXCKX/%9OEN#IX"OBL#6KUZ&)I83]Q@ZSJ8BAAZSK2P=/#
M0Q"E3M[6@Y1E-5&U_'?&N89#FW%.=9KPU0QF%R?,\;4S##X3'T:%#$86KC/W
M^-H*GAJ^)HJA'&U,3/#N-6_L:ZA*$'32?[X?\&^W[:__  S=^URGP/\ &.K_
M &/X5?M1?V7X+;[7<;+#0OBU8RW'_"M=87S9?+@_X2"XOM0\!W:V\0DOKWQ'
MX=N+R46VB1[/[\*_R*+*]O--O+34=.N[K3]0T^ZM[VPO[*XEM;RRO+65)[6[
MM+J!XY[:ZMIXTFM[B%TEAE1)(W5U!'^FI_P3!_;"M_VWOV-?A9\9+V[MI?B#
M964G@'XOV=N$0V7Q-\'QV]EKMV]O&6CM(/%5E+I7CC3;2-Y%M-*\3V-H\GVB
MWG1/Y?\ I*<%K#8W+^.,#1M1S#V64YWR1TCCJ-.3RW&3LK+ZWA:=3!5)OXJ^
M#P]VY35_ZF^C)QL\3@<QX$QU:];+_:YOD?/+66!K5(K,\%"[N_JF*J4L=3@K
M\M#&8BR48.WZ!U^;'_!3S_@HIX#_ .">?P&N_&%X;'Q!\8_&\6I:%\%OA]*X
M=M:\1Q6NZ;Q)K\$5Q!=0>"/"AFMKO7[N)XY;RXGT[0;.:&]U>&XM_J']J?\
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MJ-M]HBAN!-#'_=?@#X@?ZS<.OAO,J_/G?#5&E2IRJ3O5Q^275'!8B\FY5*N
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M')=36]I;Q1Q1RW%U>7MS;65E:0SWEY<06L$LR?H9_P .6/\ @J!_T:1XR_\
M"L^&'_S<U^N__!L[^QNVM^,?B3^VWXPTN4:=X*BOOA+\''NK<K%<^*-;L(9O
MB)XHL9'*.6T/PW>6/A*UN84FL[H^+/$UFTBW>E2(G]D=?G'B=X\YEPEQ5B>'
M>'<!D^84LMH4*>8XG,%C*DEF56/MZN&H_5,30@H86A4PU.KS<\WB:E2-XJDX
MGZ7X7> .6<7\)X;B/B/,,XR^KF=>O4RW#9>\%3B\LI2]A2Q5;ZWA:\W/%UZ>
M)J4>7D@L-3IRM)U5(_S9?^'+'_!4#_HTCQE_X5GPP_\ FYH_X<L?\%0/^C2/
M&7_A6?##_P";FO\ 2:HK\]_XF<XT_P"A'PQ_X*S;_P">!^B?\2N<$_\ 0^XI
M_P#!N4?_ #N/\V7_ (<L?\%0/^C2/&7_ (5GPP_^;FOC#]H7]F/X\_LI>-+'
MX>?M"_#77/AAXQU/0+3Q3INCZW+I=V=1\/WUY?Z=;:K8W^BW^J:7=VSW^EZC
M92&WO9'@NK.>"X2*1"M?ZM-?SQ_\'%G['2_'#]D_3OVC/"FDK<_$/]F.^FU7
M69+2U$E_JWP?\236MEXOM97C*2RQ>$]471_&,<DYFATO1K/Q;+#$CZA/+7UW
M OTALWSWBK*,EXBRW),#EV:XAX!8S K'4ZU#&XB/)@'-XK%UJ7L*N+]GAZMX
MJ47B:,HR5I7^0X]^CGD^0<)YQG?#F9YYCLRRG#K'O!X]X"I1Q&"P\N?,%!87
M"4:WMZ6$]IB:5I.,EAJT)0=XV_@[K]X_^""W_!0#P[^Q_P#M#^*?AO\ &#Q;
M9>%/@)\<= F;7=?URZ^SZ%X)\?>#+#4-6\,>*+R9DE-K9ZMIO]L^$=2%NB&[
MO-4\.7-Y(;?1D"_@Y17]*\3</9?Q7D.9\/9G&3P>9X=T9U*:@ZV'J1G"KA\5
MAW44H+$86O3IUJ3DN7FC*,[PJ33_ )DX7XCS#A+/\KXBRN45C,KQ*KPIU'-4
M<12E"=+$83$*FXSEA\50J5*-91?-RRC.%JE.FU^K?_!6/_@I5XG_ ."A7QR>
MXT.35-"_9X^&MWJ.E_!SP9>%K:>]AF9(-1^(?BFS1VB/BKQ4MO')#:N9%\,Z
M&+30K:26Z&L:EJWY245[O^S-^SI\2OVL/C?X ^ GPGTO^T?&/C[68]/AN)TG
M_LKP_I,*M=:[XIU^XMXII+/0/#>E0W6K:K<K%)+]GMC!:0W%[/;6TSRW+LDX
M/R"C@<'&AE>29)@9R<ZDU"G1P^'ISK8G%XJM)1=2K4<:N)Q6(J7J5JU24K-R
MI4HK,LRSSC+B"MC\9.OFN>9YCH1C"G"4ZE;$8BI"AA<'A*$7)4Z5-2HX;"X>
MG:G1HTX132C6JR_1S_@C+_P3<NOV\/V@4\1^/M-G7]F[X+WVEZ_\3KB1)(X/
M'&L^:MWX?^%-C<* Q/B PM>^*YH&273_  C;7L,=UI^K:SH5PW]]GQB^ WPM
M^.OP6\8?L_\ Q#\+:??_  N\:^$Y/!NH>'K*VM;"'3-+2WCBTFX\.K';M;Z)
MJ?AFXMK'4O"][:6ZMH>IZ;IUY9(CVD0'$?LA?LK?#3]C#X > _V?OA9:G^P_
M"%BTFKZ_=010ZSXV\7:CLG\2^--?:)I-^JZ]J :58/.E@TG38M.T'3FCTG2;
M"WA^F*_S^\3?$G'\;<5QS3!5\3@\KR6M[/AJE"<Z-7#QH5X55FDE&2=/,,;7
MH4L5*6L\/2AA,*I6HUHU/]#/"[PSR_@;A*658[#X;&YKG=#VG$U6<(5J.(E7
MH3I/*HN46JF7X*A7JX6,=*>)K3Q>+<;UJ,J?^7;^WI^Q7\1OV#OVBO%OP.\>
M1W&H:3!*^N?#7QQ]C>UT[XA_#R_N9TT+Q+9KEXH;Y%AETKQ)I<4TXT;Q)8:G
MIT=Q>6L-K?W?QC7^E=_P5/\ ^">?A;_@H1^SI?\ @^%+#2?C7X 34O$_P-\9
MW?[J/3?$LL$']I>%-9N%!D'A/QU;6-KI6LXWKIM_;Z)XD6WO)M!CL;K_ #>/
M&W@OQ7\./&'B?P!XZT'4?"WC/P7KVJ^&/%/AS5X#;:GHFOZ)>S:?JFF7L)+!
M+BSO()87*,\;E=\4DD;([?V+X1^(]#Q X?C]:G3I\1Y3"EA\ZPT>6'M[KDH9
MMAZ::MA\=R/VL8+DPV.6(P_NTYX:_P#&/C!X:U_#WB*7U6%6IPUF\ZV(R3%2
MYI^PL^?$93B*K3OB<!SKV4IOGQ6 EA\1[U2&*M^CW_!*K_@H[XN_X)[?'NVU
MN]N-5UKX"_$*XT_1?C3X%M7>X$NF1RF.Q\<^'[%Y4@'C#PAY\]Q98,8UC29]
M3T"XDB^W6M[8?Z-W@+QYX-^*/@OPO\1?A[XCTOQ?X'\::)8>(O"WB;1;E;K3
M-9T;4X$N;*]M9@%8+)&X$D,R17-M,LEM=0PW,,L2?Y)E?T@?\$)?^"J[_LV>
M--/_ &2?CWXC6+X ?$;70OP]\5:W>E+3X.^/M9G"?9;B[GS'8_#_ ,:7\L:Z
MMYTL6F^&/$,B>(R;*QU3Q3>/\/X[>%7^L6#J\8</X:^?9=A[YI@Z$/?SG+L/
M!OVT(0CS5,SR^E&3@DI5,9@H3P_OU\-A>?[KP$\6/]6\;2X-XAQ5N'\RQ%LJ
MQE>;Y,ES+$325&<YRY:>5YA5E%3;<:>"QLX8CW,/B<4X?W04445_#Y_=0444
M4 ?SE_\ $,3^P3_T5S]KS_PO?@S_ /."H_XAB?V"?^BN?M>?^%[\&?\ YP5?
MT:45^B_\1<\3?^BWS[_P?A/_ )U'YO\ \0?\+_\ HAL@_P#!&,_^>QF:+I5O
MH6C:3HEH\TEIHVF6&E6LERR/<26^GVL5I"\[Q1PQM,T<*M*T<42,Y8I&BD*-
M.BBOSN4G*4I2;<I2<I-[N4FY2;VU<I-O1:MZ'Z/&*C&,8I*,8QC%+91BE&*6
M^BC&*6KT2U>X5^6?[=O_  2$_93_ ."@OCOPI\3/B[J'Q1\%>.?"WAV3PI)X
M@^$>N^$- N_%&A)>O?Z59^*D\6>!/&]O?OH%Q<ZD-'N[*'3;R.#5+JTOKB^M
M8-,AT_\ 4RBO3R;.\WX>Q]/,\CS'%Y5F%*G5I0Q>#J*G65*O!0K4VY4ZT)4Z
MD$E.%2E4B^6,DHSC&<?+SK(LGXCP%3*\]RW"9MEU6I2JSP>-INI1=6A-U*-1
M*-2C.-2E-MPG3K4Y+FE%N4)SA+^<O_B&)_8)_P"BN?M>?^%[\&?_ )P5'_$,
M3^P3_P!%<_:\_P#"]^#/_P X*OZ-**^Q_P"(N>)O_1;Y]_X/PG_SJ/C/^(/^
M%_\ T0V0?^",9_\ /8_,#]@K_@DU^SI_P3M\8^//&_P4\:?&OQ1JOQ#\,Z?X
M5UJW^*7B/P+K>GVNGZ;J@U>";2XO"?PX\$W,%Z]R DLEW=WL#0?*EO')^]K]
M/Z**^.SC.LVX@Q]7-,[S#$YGF-:%&G5QF+E"5>I"A3]E1A*5.CAXM4Z?N1M2
M34=W)ZGVF39)E'#N7TLJR/+\-E>6T9UJE+!82,X4*=3$5/:UIQC4K8B:=6I[
M\[U9)RV45H%%%%>6>H?FG^TQ_P $B/V _P!JJ]OM?^('P*T7PQXWU%Y9KKX@
M?"FXF^&_BFZNYE"RW^K+X>$/AWQ+J#A4S>^*_#^NW*^6H615+JWXZ?$O_@UJ
M^&M]-=3_  =_:T\<^%X!-))8Z7\2_AQH'CN9K<H!%:W6O>%M?^'*),K[GDOX
M?#DD;IB)=-C.9:_JWHK[W(_%#C_AVE##Y5Q3FE/"TDHT\)BZE/,\+3C'10IT
M<SI8WV4$ERJ%*M3A&-E&$4ER_G^>^%?A[Q'5J8C->%,JJ8JJY2J8O!TZF5XJ
MI.6KG4K975P7M9MOF<ZM&I.4KN4Y-OF_BCUC_@US_:-@:4>'_P!IOX)ZF@NW
M2!M8\/>.M#:2Q!E\JYE2RL?$0ANW A+V2//#&9)0M_*(4,YH_P#P:Y_M&SM$
M/$'[3?P3TQ#=HD[:/X>\=:XT=B3%YMS$E[8^'1-=H#,4LG>"&0QQ!K^(3.8/
M[7**^L_XF!\4.3D_M?+;_P#/S^P<L]IM;>_+Y_P]^EM#Y'_B7CPLY^?^Q\RM
M_P ^_P"W\T]GO?:W/Y?Q=O/4_E%^&W_!K3\.;*:UG^+_ .UOXV\36Y</>Z7\
M-OAIH7@>98]N#;VNO>)_$?Q#21]X+B[E\.1J5;ROL0*^:_[$_LS_ /!(/]@'
M]E:]T_7_  %\"M'\5^.--E2XL_B!\6;F7XD>)[2[B</;W^E0Z\K^&/#>HVQ&
M(-1\+>'-#OE!;=<,6)/Z8T5\IGGBCX@<14IX?-.*<TGA:B<:F$PE2GEF%J1E
M=.%2CEE+!>T@TW%PJUJD)1TE"2;YOKLB\*_#SARK3Q&5<*95#%4G&5/%XRG4
MS3%4YQLU.G6S2KC52FFE)3I4*<XRUC.+2Y2BBBO@3] "BBB@ KFO&GA#P[\0
MO!WBSP#XNTV'6?"?CCPUKOA#Q/I%R";?5?#OB72[K1=:TV<#DPWVFWMS:R@<
ME)6KI:*J$YTIPJ4YRIU*<X5*=2$G&=.I3G"I3G"46I1G"I3A.$HM2C.$9)IQ
M34SA"K"=*I"-2G5A.G4ISBI0J4ZD)TZE.<9)QE"=.I.$XR3C*$Y1::DT_P"<
MO_B&)_8)_P"BN?M>?^%[\&?_ )P5'_$,3^P3_P!%<_:\_P#"]^#/_P X*OZ-
M**_0_P#B+GB;_P!%OGW_ (/PG_SJ/SG_ (@_X7_]$-D'_@C&?_/8_G5LO^#9
M']@2UO+2ZG^)W[6>I06UU;W$VG7OQ ^$T=GJ$4,J2265V^G? W3]02UND4P7
M#V%_97BQ2.;6[MIPDR?T.:9IFG:)INGZ-H]C::7I.DV-IIFEZ986\5I8Z=IU
MA;QVMC8V5K J0VUI:6T45O;6\*)%##&D<:JB@"]17SN?\7\3\4_55Q'GN89R
ML%[9X2..JTYQP[K^S59TXTL-A8J514J:E*49RY8**E&-XR^DX?X.X6X4>*?#
M>0Y=DKQWL5C)8&E4A+$+#^T=&-657%8J3C2=6HXQC*$>:<I.,I6E$K\4OVJ?
M^"$_[+?[8OQS\:_M _&'XS?M4R^-/&TVGB;3O#_C?X56?A?P[I>D:=:Z5I'A
M[PMIFJ_!;6KW3-#TVSM$$%M/JE]<374MYJ-]=W>HWUY=3_M;17-D7$>>\,XJ
MICN'\TQ64XRM0EAJF)P;HQK2P\IPJ2H\];"XKEA*=.G*2@J;ER14I2BE Z<^
MX:R'BC"4L!Q#E6$S?!4:\<53PN,5>5&.(C"=*-;DHXO"\TX4ZE2,'-U%'GDX
MQC)N9_.7_P 0Q/[!/_17/VO/_"]^#/\ \X*OLS]A[_@C-^R9^P/\6=2^-7PI
MUSXP^-O'5YX3U'P?IUW\6O$7@C7K/PSI^KW=C<:M?>';7PI\.O!+6FLZA!81
MZ9/J-W/?O'I-Q?V-JEO'J-Z9_P!:**]_,?$SQ S; XK+<RXNSK&8#&T94,7A
M*U>A[+$4).#E2J^RR^A-TY.$.:*JP4DN67-%RC+Y_+O##P]RC'87,\LX/R3!
M9A@:T<1@\71P^(]MAZ\%-0JTO:YAB*:J04Y\LG1FXM\T>62C.)1117PQ]V%%
M%% !7YW_ +?/_!,C]G3_ (*+67PYA^-VH?$7PSJOPONM>D\-^)_A9K'A;0O$
M,VG^)8M/75=!U:Y\4^#/&EE?:-)<Z5I^H6T"Z?!=65];R26EY##>ZA!=_HA1
M7HY5FV9Y%C\/FF3X[$Y;F.%<WA\9A)JG7I>UISHU%&4J=6+52E4G3G&=*I&4
M9-.+M%Q\[-LHRO/LOQ&59S@,-F>6XI4UB,%BX.I0K>RJPK4W*,:E*:=.K3A4
MA*%6G*,HIJ2O)2_G+_XAB?V"?^BN?M>?^%[\&?\ YP5'_$,3^P3_ -%<_:\_
M\+WX,_\ S@J_HTHK[3_B+GB;_P!%OGW_ (/PG_SJ/B/^(/\ A?\ ]$-D'_@C
M&?\ SV/-_@]\-K;X.?"SX?\ PHL?%7B_QMIWPZ\)Z+X-TOQ3X^O=(U+QEJ^E
M>'[*+3=+F\1ZCH6A^'-+U'4X=/M[:UFOX-%LI;T0+<WHN+Z6YNI_2***_/ZU
M:KB*U;$5INI6KU:M>M4:A%U*M:I.K5FXTX4X)SJ5*DVH4Z<$YOEA!6BOT.A1
MI8:C1P]""IT</2I4*--.<E3HT:=.C2IJ52=6HU"E2IP3G4J3:@N:<Y7E+\P/
MV]?^"2O[,?\ P40\8^ _'WQFUSXL>$?%G@#PUJ'A"RU?X4:]X-T.XUWP[=ZH
M=:LM-\1GQ=X \<BZAT#4KG6+K1!IW]EF!_$.L_:_MWG6OV/X*_XAB?V"?^BN
M?M>?^%[\&?\ YP5?T:45]CE?B1Q[DN PV5Y5Q9G. R[!PE3PN#H5Z'L</3E4
MJ57"DJN Q$XP]I5J2475E&+G)148OE7QF:>&? &=YAB<US;A')<?F.-G&IB\
M9B*&(=?$5(TZ=)5*KI9AAX2G[.E3@Y*E&4E"+DY27,_YR_\ B&)_8)_Z*Y^U
MY_X7OP9_^<%7Z+?L#?\ !+G]F[_@G3-\1[_X)ZE\2O%6N_$^+P_9Z]XD^*VM
M>%-?UNPTGPVVI36>AZ!/X6\$^"K73=*N[S5)K_5HGL[FXU.[M=,>YN7CTNPB
M@_1ZBIS;Q&X[SW 5\KSCBK.,PR[%>S6)P>(KT'0KJE4A6IJHJ6!P\Y1C5IPG
MR^U47*$>:,TE$K*/#;@+(<PP^:Y-PGDV79EA?:/#8W#4*ZKT'5I3HU)4I5L?
MB81E*E4J4W+V3DHSERR@VY!7F_QA^&UM\8_A9\0/A1?>*O%_@G3OB+X3UKP;
MJGBGP#>Z1IOC+2-*\064NFZI-X<U'7=#\1Z7IVIS:?<7-K#?SZ+>RV0G:YLA
M;WT5M=0>D45\A1K5</6HXBC-TZU"K2KT:B4).G5HU(5:4U&I"I!N%2G3FE.G
M4@W!<T)J\7]C7HTL31K8>O!5*.(I5:%:FW.*J4:U.I1JTW*G.E42G2JU(-PJ
M4YI3?+.$K2C_ #E_\0Q/[!/_ $5S]KS_ ,+WX,__ #@J/^(8G]@G_HKG[7G_
M (7OP9_^<%7]&E%?H'_$7/$W_HM\^_\ !^$_^=1^>?\ $'_"_P#Z(;(/_!&,
M_P#GL>"_LQ?LX?#;]DGX&?#_ /9\^$MOJ<7@;X=Z9<6&FW6NW%C>>(=9O-0U
M&\UC6=?\17VFZ=I%A>ZYK>KZA>ZEJ-Q9Z7IUGY]P8K*QL[.*WM8?>J**^"Q6
M*Q..Q6)QN,KU<3B\77K8G%8FM)SK5\17J2JUJU6;2YJE2I.4Y.T5=Z1C%1C'
M] PF$PV PN&P."H4L+@\'0HX7"X:A%0HX?#X>G"E1HTH)OEITZ<(PBKR=E=R
ME)RE(HHHKG.@*P?%/ACP_P"-O#'B/P9XLTJTU[PMXNT'5_#'B70[]#)8ZSX?
MU_3[C2M9TJ]C5D9[34=.N[FSN45E+0S.H8$Y&]150G*G.%2$I0G"49PG"3C.
M$X2C.$X2BU*,X3A"<91:E&48RBU**:F<(5(3IU(QG3J0E3J0G%2A.$XRA.$X
MR3C*$X3G"<9)QE&<HR3C*2?\YTO_  ;&?L$222.OQ7_:YA5W=UAB\??!TQQ*
MS$B*,S? :68I&"%0RRRR%0"\CMEBS_B&)_8)_P"BN?M>?^%[\&?_ )P5?T:4
M5^A_\1<\3?\ HM\^_P#!^$_^=1^<_P#$'_"__HAN'_\ P1B__GL?SE_\0Q/[
M!/\ T5S]KS_PO?@S_P#."K]"?V"_^"4_[+W_  3OU7QUXD^#$_Q$\6^,/']C
MI^C:EXR^*^L^%_$'B+2?#MA.;Q_#?AV;PMX,\%6&EZ/J6HK;:EK"-I]S>:G>
M:?IANKUX--L8(/TKHKS\U\1^/,\P&(RO-^*\YQ^78I0CB<'7Q%'V->,*D*L8
M551P.&G."J4X3<'54).$>>$TE$]'*?#7@'(LPP^:Y1PEDN7YCA'.6%QE##UO
M;X>4Z<Z4ITG6Q^)A";IU)P4U2<XJ<N2=.4G(****^*/MPK^6O_@X'_X)@I\2
M?"VJ?MT? WPZ7^(/@C28C\??#6D6Q:;QCX&TJ!(8/B/;VL()FU_P/81I#XF=
M$9[_ ,&VZ:C*\;>%W%]_4I44T,-S#-;W$,5Q;W$4D,\$T:2PS0RH8Y89HI R
M212(S))&ZLCHQ5@02*^IX-XMS/@GB# Y_E<VZF&GR8K"RG*-',,!5E!8O XB
MU_<K4U>G/EE+#XBGA\137/2:J?*<:<(97QQP[CN'\U@E3Q,/:83%QA&5?+L?
M2C-X3'X?FM^\HU':I#FC'$8:IB,-4?)53I_Y$E%?N5_P6V_X)D2?L1?&A/BO
M\)M G@_9@^,^K7,WAJ.TB9[#X7^/IUN]1U?X8SNI?[-I$]M!<:[X!>X\DSZ(
MFIZ#$+J7PE=W]W^&M?Z5\-\0Y9Q5DF7Y]E%;VV!S"BJD$W'VN'JQM#$83$PC
M*7LL5A*RG0KTV])1C.'-2K49S_S'XFX<S3A//,PX?SBC[''9=7=*;2E['$49
M7GA\9AIRC%U<+BZ#A7H5$M82E":C5HUH0_MK_P"""?\ P577XT>&-(_8J_:
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M>"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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9<U2M@L'5J2M%**YJE6I*T4HKFM%)))?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
